Angioimmunoblastic T-cell lymphoma management.
Angioimmunoblastic T-cell lymphoma (AITL) is a frequent subtype of peripheral T-cell lymphoma (PTCL) that is clinically characterized by generalized lymphadenopathy, extranodal involvement, advanced stage at presentation, hypergammaglobulinemia, and significant immune dysregulation resulting in infections as the most common cause of death. Recent advances in pathobiology of AITL have improved our understanding of it as a clonal T-cell disorder and of its effect on B cells in the tumor microenvironment. Reponses to first-line therapies have largely been dismal. In this review, we discuss the clinical features, pathobiology, prognostic models, standard therapy, and newer therapeutic agents used and their implications for the future.
UNMC Oncology/Hematology Division, Nebraska Medical Center, Omaha, NE.
Kailash
K
Mosalpuria
UNMC Oncology/Hematology Division, Nebraska Medical Center, Omaha, NE.
R Gregory
RG
Bociek
UNMC Oncology/Hematology Division, Nebraska Medical Center, Omaha, NE. Electronic address: jmvose@unmc.edu.
Julie M
JM
Vose
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
D000970:Antineoplastic Agents